<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="255">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01211691</url>
  </required_header>
  <id_info>
    <org_study_id>KB004-01</org_study_id>
    <nct_id>NCT01211691</nct_id>
  </id_info>
  <brief_title>Study of KB004 in Subjects With Hematologic Malignancies</brief_title>
  <official_title>Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KaloBios Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KaloBios Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine a maximum tolerated dose (MTD) for KB004 when
      administered once weekly by intravenous (IV) infusion to subjects with EphA3-expressing
      hematologic malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Determine a possible maximum tolerated dose (MTD)</measure>
    <time_frame>Once weekly for the first three weeks of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determination of a possible MTD as assessed by the number of subjects experiencing KB004-related adverse events that are considered dose limiting in nature</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Assessed through weekly subject evaluations for the entire duration of study participation (up to 1 year)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of subjects with adverse events and laboratory abnormalities as a measure of safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile</measure>
    <time_frame>For Dosing Cycle 1: Baseline, at end of study drug administration &amp; 1hr, 3hrs, 6 hrs, 2d, 3d, 5d, 8d, and 15d following study drug administration.  Thereafter Day 1 of Dosing Cycles 2, 3, 6, 9, 12 &amp; 15 (Dosing Cycles each @ 3wks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The amount of KB004 in subject serum over time as a measure of its pharmacokinetic profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects on relevant tumor cell subpopulations</measure>
    <time_frame>Baseline and Day 1 of Dosing Cycles 2 (optional), 3, 6, 9, 12, and 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in the amount of EphA3-expressing tumor cells by subpopulation in subject blood or bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess immunogenicity</measure>
    <time_frame>Baseline, Day 8, and Day 15 of Dosing Cycle 1 and Day 1 of Dosing Cycles 2, 3, 6, 9, 12, and 15</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The development of anti-KB004 antibodies in subject blood as a measure of immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine clinical activity</measure>
    <time_frame>Baseline and Day 1 of Dosing Cycles 2 (optional), 3, 6, 9, 12, and 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of subject with reduced hematologic malignancy signs and symptoms as a measure of clinical activity</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Acute Lymphocytic Leukemia (ALL)</condition>
  <condition>Chronic Myelogenous Leukemia (CML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <condition>Myeloproliferative Neoplasms (MPN)</condition>
  <arm_group>
    <arm_group_label>KB004, Monoclonal Antibody 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion 1x Weekly for a 21 day dosing cycle
Up to 17 cycles at 4 planned dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KB004, Monoclonal Antibody 70mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion 1x Weekly for a 21 day dosing cycle
Up to 17 cycles at 4 planned dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KB004, Monoclonal Antibody 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion 1x Weekly for a 21 day dosing cycle
Up to 17 cycles at 4 planned dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KB004, Monoclonal Antibody 700mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion 1x Weekly for a 21 day dosing cycle
Up to 17 cycles at 4 planned dose levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KB004, Monoclonal Antibody</intervention_name>
    <description>4 planned treatment arms</description>
    <arm_group_label>KB004, Monoclonal Antibody 20mg</arm_group_label>
    <arm_group_label>KB004, Monoclonal Antibody 70mg</arm_group_label>
    <arm_group_label>KB004, Monoclonal Antibody 200mg</arm_group_label>
    <arm_group_label>KB004, Monoclonal Antibody 700mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed hematologic malignancy, including Acute Myeloid Leukemia (AML), Chronic
             Myelogenous Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Myelodysplastic
             Syndrome (MDS), Myeloproliferative Neoplasms (MPN)

          -  EphA3 expression

          -  Eastern Cooperative Oncology Group (ECOG) â‰¤2

          -  Acceptable laboratory results

          -  Corrected QT-Bazett's formula (QTcB) &lt;0.48 seconds

          -  Acceptable level of residual toxicity from prior therapy

          -  No standard therapies available

        Exclusion Criteria:

          -  Active central nervous system (CNS) involvement due to leukemia

          -  Recent major surgery

          -  Ongoing surgical or wound healing complications

          -  History of bleeding diathesis

          -  Uncontrolled hypertension

          -  Significant intercurrent illness

          -  Pregnant or breastfeeding women

          -  Unable or unwilling to provide written informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Leff, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>KaloBios Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joshua Pelham</last_name>
    <phone>650-243-3125</phone>
    <email>jpelham@kalobios.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3007</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>October 7, 2011</lastchanged_date>
  <firstreceived_date>September 24, 2010</firstreceived_date>
  <responsible_party>
  </responsible_party>
  <keyword>Hematologic</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Malignancies</keyword>
  <keyword>Myeloproliferative Neoplasms</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
</clinical_study>
